Drugmaker Roche <ROG.S> on Friday said it had received Emergency Use Authorization from the U.S. Food and Drug Administration for a test to quickly detect whether a patient has SARS-CoV-2 or one of two forms of influenza
"With the approaching flu season, this new test is particularly important as SARS-CoV-2 and influenza infections can hardly be differentiated by symptoms alone. Now, with a single test, healthcare professionals can confidently provide the right diagnosis and most effective treatment plan for their patients," Roche diagnostics head Thomas Schinecker said in a statement.
(Reporting by Brenna Hughes Neghaiwi; Editing by Riham Alkousaa)
